Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseobservationalRules rewrite

Not a traditional drug phase: Non-interventional for IBD

This is a French prospective longitudinal watch-and-measure (no experimental treatment required) multicentre cohort study. Primary objective : to assess prospectively the presence and the extent of safety concerns (cancer, serious infections, arterial and venous thrombotic events) in patients with CD and UC and treated with JAKi, anti-IL23p19, and S1p modulators.

Official registry: https://clinicaltrials.gov/study/NCT06089590 · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · enrollment listed as 6,000

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 6,000 people at 2 sites. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Ibd CAncer and seRious Infections in France (I-CARE 2)

Interventions: Non-interventional

Primary outcome (registry wording): Number of SAE declared by patients (cancer, serious infections, arterial and venous thrombotic events)

Who it is for (from inclusion criteria)

  • Ages 18 Years to 75 Years
  • Patient with an established diagnosis of Crohn's disease, ulcerative colitis or IBD unclassified based on usual radiological, endoscopic or histological criteria

Public study contact (from the registry)

Marie Coisnon

09 72 57 61 60

mcoisnon@getaid.org

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

2 listed

Related recruiting trials in this snapshot

FAQ about this NCT record

Is NCT06089590 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06089590?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06089590?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary